Track every patent expiry on the LOE calendar. Match each window to global trade size, active patent count, and supplier readiness.
The LOE catalog holds 800 patent-expiry rows across major regulated markets. The 2026 window opens with peginesatide (June) and steps through famotidine (July, $24M trade), sugammadex (July), pantoprazole (December, $103M trade). 2027 brings ropivacaine, mipomersen, oxcarbazepine (11 active patents remaining). Olaparib's window opens in 2027 with the active patent stack still in the high single digits. The feed below carries the next twelve material windows.
Default surface is the next 24 months across all markets. Scope to a specific market (US, EU, BR), a therapy area, or a portfolio of molecules in development.
Each patent expiry is joined to current global trade size, active patent count, and (where available) the active DMF holder count. Three signals per window.
Citation-anchored brief with the priority windows, the FTO complexity (active patent count), and the supplier readiness (active DMFs). Handoff to portfolio prioritisation.
Patent expiries 18 to 24 months out are the actionable ones for ANDA filing or in-licensing. Closer-in windows are too late; further-out windows are not yet portfolio-ready.
Each LOE window carries the molecule's current global trade size as the commercial signal. A $100M trade window matters; a $0.3M trade window typically does not justify the entry cost.
A molecule with one active patent has a clean FTO path; a molecule with 11 active patents (oxcarbazepine, diclofenac) carries litigation risk. The brief surfaces both numbers per window.
Active US DMF count signals whether API supply will be ready at LOE. Zero DMFs is the reshoring or licensing trigger; many DMFs is the crowded-entry warning.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Plants linked to the top 12 LOE candidates · inspection class shown · DMF holder posture into the LOE window.
The LOE calendar is the forward-looking portfolio sequencing feed. PharmaDB matches every patent expiry to current global trade size, active patent count, and active DMF coverage, and surfaces the priority windows in chronological order. The view is v_loss_of_exclusivity; the joins are to molecule_country_flow and api_docs.
Each molecule-market pair with at least one active patent and a defined latest-patent-expiry date. The underlying view is v_loss_of_exclusivity. US is the primary surface; EU and BR market windows are also tracked.
LOE refers to the latest patent expiry on the standard 20-year-from-filing horizon. Olaparib's earliest patents expired earlier; the latest patent in the stack is the actionable date for clean FTO. The brief surfaces the latest expiry as the LOE window.
A patent expiry in the next 18 to 24 months combined with at least $25M of 2024 global trade and an active patent count under 5. Pantoprazole is the textbook fit on the current calendar.
Limited-competition targets identifies molecules with little ANDA activity right now. The LOE calendar is the forward-looking version: which molecules will open up an entry window in the next 24 months. Run as a paired view for portfolio sequencing.
Yes. The market filter on v_loss_of_exclusivity covers US, EU, and BR. Other regulated markets are added as patent registry coverage expands. The brief surfaces the market on each window.
Patent registry refreshes monthly. LOE windows recompute on every refresh. The catalog row carries the last-computed timestamp surfaced on every result page.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.